Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate

Journal of Cutaneous Pathology

Volumn 35, Issue 11, 2008, Pages 1003-1006

  Thomison, John ^a   McCarter, Martin ^a   McClain, Damon ^b   Golitz, Loren E ^a   Goldenberg, Gary ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b Bureau of Medicine and Surgery   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; IMATINIB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DERMATOFIBROSARCOMA PROTUBERANS; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR VOLUME;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; COLLAGEN; COMBINED MODALITY THERAPY; DERMATOFIBROSARCOMA; FEMALE; HUMANS; HYALIN; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 53749092204     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00948.x     Document Type: Article

References (12)

1. Shimizu A, O'Brien KP, Sjöblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type I1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999 59 : 3719.
2. Khachemoune A, Barkoe D, Braun M, Davison SP. Dermatofibrosarcoma protuberans of the forehead and scalp with involvement of the outer calvarial plate: multistaged repair with the use of skin expanders. Dermatol Surg 2005 31 : 115.
3. Simman R, DeFranzo A, Sanger C, Thompson J. Dermatofibrosarcoma protuberans of the face: surgical management. J Craniofac Surg 2005 16 : 439.
4. Thomas CJ, Wood GC, Marks VJ. Mohs micrographic surgery in the treatment of rare aggressive cutaneous tumors: the Geisinger experience. Dermatol Surg 2007 33 : 333.
5. U.S. Food and Drug Administration Office of Oncology Drug Products 2007. http://www.fda.gov/Cder/Offices/OODP/whatsnew/imatinib200610.htm (accessed June 18).
6. ® Package Insert 2007. http://www.pharma.us. novartis.com/product/pi/pdf/Gleevec.pdf accessed June 18).
7. Wiess SW, Goldblum JR. Fibrohistiocytic tumors of intermediate malignancy. In Weiss SW, Goldblum JR, eds. Enzinger and Weiss's Soft Tissue Tumors, 4th ed. Elsevier Sciences, St Louis, MO, USA.
8. Weiss SW, Nickoloff BJ. CD-34 is expressed by a distinctive cell population in peripheral nerve, nerve sheath tumors, and related lesions. Amer J Surg Pathol 1993 17 : 1039.
9. Terrier-Lacombe MJ, Guillou L, Maire G, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data-a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003 27 : 27.
10. Kanitakis J, Bourchany D, Claudy A. Expression of the CD10 antigen (neutral endopeptidase) by mesenchymal tumors of the skin. Anticancer Res 2000 20 : 3539.
11. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001 61 : 5778.
12. Sciot R, Debiec-Rychter M. GIST under imatinib therapy. Semin Diagn Pathol 2006 23 : 84.